Cargando…

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL

We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuta, S, Matsuo, K, Maeda, T, Yujiri, T, Hatta, Y, Kimura, Y, Ueda, Y, Kanamori, H, Usui, N, Akiyama, H, Takada, S, Yokota, A, Takatsuka, Y, Tamaki, S, Imai, K, Moriuchi, Y, Miyazaki, Y, Ohtake, S, Ohnishi, K, Naoe, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366071/
https://www.ncbi.nlm.nih.gov/pubmed/22829974
http://dx.doi.org/10.1038/bcj.2012.18
_version_ 1782234708422164480
author Mizuta, S
Matsuo, K
Maeda, T
Yujiri, T
Hatta, Y
Kimura, Y
Ueda, Y
Kanamori, H
Usui, N
Akiyama, H
Takada, S
Yokota, A
Takatsuka, Y
Tamaki, S
Imai, K
Moriuchi, Y
Miyazaki, Y
Ohtake, S
Ohnishi, K
Naoe, T
author_facet Mizuta, S
Matsuo, K
Maeda, T
Yujiri, T
Hatta, Y
Kimura, Y
Ueda, Y
Kanamori, H
Usui, N
Akiyama, H
Takada, S
Yokota, A
Takatsuka, Y
Tamaki, S
Imai, K
Moriuchi, Y
Miyazaki, Y
Ohtake, S
Ohnishi, K
Naoe, T
author_sort Mizuta, S
collection PubMed
description We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted.
format Online
Article
Text
id pubmed-3366071
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33660712012-06-04 Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL Mizuta, S Matsuo, K Maeda, T Yujiri, T Hatta, Y Kimura, Y Ueda, Y Kanamori, H Usui, N Akiyama, H Takada, S Yokota, A Takatsuka, Y Tamaki, S Imai, K Moriuchi, Y Miyazaki, Y Ohtake, S Ohnishi, K Naoe, T Blood Cancer J Original Article We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted. Nature Publishing Group 2012-05 2012-05-18 /pmc/articles/PMC3366071/ /pubmed/22829974 http://dx.doi.org/10.1038/bcj.2012.18 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Mizuta, S
Matsuo, K
Maeda, T
Yujiri, T
Hatta, Y
Kimura, Y
Ueda, Y
Kanamori, H
Usui, N
Akiyama, H
Takada, S
Yokota, A
Takatsuka, Y
Tamaki, S
Imai, K
Moriuchi, Y
Miyazaki, Y
Ohtake, S
Ohnishi, K
Naoe, T
Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title_full Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title_fullStr Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title_full_unstemmed Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title_short Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
title_sort prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in bcr–abl-positive all
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366071/
https://www.ncbi.nlm.nih.gov/pubmed/22829974
http://dx.doi.org/10.1038/bcj.2012.18
work_keys_str_mv AT mizutas prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT matsuok prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT maedat prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT yujirit prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT hattay prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT kimuray prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT ueday prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT kanamorih prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT usuin prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT akiyamah prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT takadas prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT yokotaa prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT takatsukay prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT tamakis prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT imaik prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT moriuchiy prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT miyazakiy prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT ohtakes prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT ohnishik prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall
AT naoet prognosticfactorsinfluencingclinicaloutcomeofallogeneichematopoieticstemcelltransplantationfollowingimatinibbasedtherapyinbcrablpositiveall